Skip to main content
TISSUE REPAIR LTD logo

TISSUE REPAIR LTD — Investor Relations & Filings

Ticker · TRP ISIN · AU0000180887 ASX Professional, scientific and technical activities
Open in API
Filings indexed 139 across all filing types
Latest filing 2024-09-19 Regulatory Filings
Country AU Australia
Listing ASX TRP

About TISSUE REPAIR LTD

https://tissuerepair.com.au/

Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing and skin repair agents. The company’s core technology centers on Glucoprime, a proprietary yeast-derived beta-glucan designed to stimulate the innate immune system and accelerate the body's natural healing processes. Its lead candidate, TR-987, is being developed for the treatment of chronic wounds, such as venous leg ulcers, and for use in post-procedural recovery following aesthetic treatments. By targeting the inflammatory phase of wound healing, the technology aims to improve clinical outcomes and reduce recovery times. The company focuses on addressing unmet needs in both the medical wound care and cosmetic dermatology markets through its specialized biological platform.

Recent filings

Filing Released Lang Actions
TOV: TRP - Panel Accepts Undertaking and Declines to Conduct 3 pages 281.6KB
Regulatory Filings Classification · 95% confidence The document is a media release from the Takeovers Panel regarding an application by Tissue Repair Ltd (TRP) related to board restructuring and shareholder notices. It includes details about undertakings given by Mr Charara and Spark Capital Pty Ltd, and the Panel's decision to decline proceedings. The document is a regulatory announcement about a dispute and the Panel's decision, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It also includes an official undertaking under the Australian Securities and Investments Commission Act. The document is short (4289 characters) and serves as a formal regulatory announcement about corporate governance and takeover panel decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-19 English
Notification regarding unquoted securities - TRP 7 pages 21.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities under an employee incentive scheme by Tissue Repair Ltd. It includes specifics such as security descriptions, issue dates, quantities, and compliance with ASX listing rules. The content focuses on the announcement of new securities issued, which aligns with capital structure changes. There is no indication of financial performance data, management discussion, or regulatory certifications. The document is not a report but an official notification of securities issuance, fitting the category of Share Issue/Capital Change.
2024-09-18 English
Re- Takeovers Panel - Media Release 1 page 106.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 September 2024, referencing a media release from the Takeovers Panel dated 29 August. It discusses a notice related to a potential meeting requisition involving directors but does not contain financial data, detailed reports, or formal filings such as merger documents. The content is brief (1169 characters) and serves as a regulatory update or announcement rather than a full report or detailed filing. It does not fit into categories like M&A Activity or Management Reports but aligns with general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-09-01 English
2024 Annual General Meeting Date 1 page 97.1KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 30 August 2024, notifying shareholders of the date for the 2024 Annual General Meeting (AGM) to be held on 25 October 2024. It references the ASX Listing Rule 3.13.1 and mentions that further details including the Notice of Meeting will be provided later. The document does not contain any financial data, management discussion, or detailed report content. It is a brief announcement about the scheduling of the AGM, not the AGM materials themselves or any other report. The document length is short (1359 characters), consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2024-08-29 English
TOV: TRP - Panel Receives Application 2 pages 196.4KB
Regulatory Filings Classification · 95% confidence The document is a media release from the Takeovers Panel regarding an application received from Tissue Repair Ltd about an alleged undisclosed association between certain shareholders and related board restructuring matters. It discusses procedural details, requests for interim and final orders, and does not contain financial data, earnings, or report content. It is an announcement related to a regulatory or legal proceeding concerning shareholder and board issues, but it is not a full legal proceedings report or audit report. Given the nature of the content and the absence of financial statements or detailed legal case updates, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and compliance-related documents that do not fit other categories.
2024-08-28 English
Appendix 4E and Annual Report 30 June 2024 51 pages 2.1MB
Annual Report Classification · 100% confidence The document is titled 'Tissue Repair Ltd Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2024. It includes detailed financial results, directors' report, auditor's report, consolidated financial statements, and other comprehensive information typical of a full annual report. The presence of an auditor's report with an unmodified opinion, detailed financial statements, directors' declarations, and extensive corporate governance information confirms this is a full annual report filing. The document is approximately 15,000 characters long, indicating it is the full report rather than a brief announcement or notice. The mention of the Annual Report being attached within the document further supports that this is the actual report. Therefore, the appropriate classification is Annual Report (10-K).
2024-08-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.